Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1336-1343

  Smith, I E ^a   O'Brien, M E R ^a   Talbot, D C ^a   Nicolsan, M C ^a   Mansi, J L ^a   Hickish, T F ^a   Norton, A ^a   Ashley, S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOMYCIN; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; VOMITING;

EID: 0035281498     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1336     Document Type: Article

References (25)

1. Benefits of polychemotherapy in advanced non small cell lung bronchogenic carcinoma
2. Chemotherapy can prolong survival in patients with advanced non small cell lung cancer: Report of a Canadian multicentre randomized trial
3. Cisplatin-cyclophosphamidemitomycin combination chemotherapy with supportive care versus supportive care alone for the treatment of metastatic non-small cell lung cancer
4. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
5. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
6. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized trials
7. Symptom relief with MVP (mitomycin C. vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
8. Randomized study of Navelbine and cisplatin versus vindesine and cisplatin versus Navelbine alone in 612 patients with advanced non-small cell lung cancer (NSCLC)
9. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer: The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
10. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer
11. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
12. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
13. Results of a phase III trial comparing taxol-cisplatin (TC) regimens to etoposide-cisplatin (EC) in non-small cell lung cancer (NSCLC)
14. Patient preference for extended palliative chemotherapy for non-small cell lung cancer
15. Reporting results of cancer treatment
16. Non parametric estimation from incomplete observation
17. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
18. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials
19. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples
20. Clinical benefit from palliative chemotherapy in non-small cell lung cancer extends to the elderly and those with poor prognostic factors
21. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
22. Improving quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies
23. Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small-cell lung cancer (NSCLC)
24. Defining the role of paclitaxel in lung cancer: Summary of recent studies and implications for future directions